SARS-CoV-2 M is a chymotrypsin-like cysteine protease playing a relevant role during the replication and infectivity of SARS-CoV-2, the coronavirus responsible for COVID-19. The binding site of M is characterized by the presence of a catalytic Cys145 which carries out the hydrolytic activity of the enzyme. As a consequence, several M inhibitors have been proposed to date in order to fight the COVID-19 pandemic. In our work, we designed, synthesized and biologically evaluated , a novel inhibitor of SARS-CoV-2 M bearing a trifluoromethyl diazirine moiety. displayed in vitro inhibition activity against SARS-CoV-2 M at a low micromolar level (IC = 4.1 μM) in a FRET-based assay. Moreover, an inhibition assay against PL revealed lack of inhibition, assuring the selectivity of the compound for the M. Furthermore, the target compound was docked within the binding site of the enzyme to predict the established intermolecular interactions in silico. was subsequently tested on the HCT-8 cell line to evaluate its effect on human cells' viability, displaying good tolerability, demonstrating the promising biological compatibility and activity of a trifluoromethyl diazirine moiety in the design and development of SARS-CoV-2 M binders.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864213 | PMC |
http://dx.doi.org/10.3390/molecules28020514 | DOI Listing |
Acc Chem Res
November 2024
Department of Chemistry, University of Victoria, Victoria, British Columbia V8W 3V6, Canada.
ACS Med Chem Lett
July 2024
Department of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Antibiotic-resistant bacteria are a global health concern, necessitating the development of antibiotics working through new or underutilized mechanisms. Functionalized amino dihydropyrimidines have previously demonstrated potential as antibacterial agents, but they had limited potency, and their biological mechanism was not understood. To further evaluate their potential, focused libraries were prepared and screened for bacterial growth inhibition, and these compounds provided additional insights into the structure-activity relationships, allowing for the preparation of compounds that inhibited all strains of with an MIC of 2 μg/mL.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
April 2024
Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, 610065, China.
Organic electrochemical transistors (OECTs) rely on both efficient ionic doping/de-doping process and carrier transport in the mixed ionic-electronic channel under the modulation of gate bias. Moreover, channels that hold photopatterning capability are highly desired to minimize parasitic capacitance and simplify the fabrication process/cost. However, yielding photo-patternable channels with both precise/robust patterning capability and controllable ionic-electronic coupling is still challenging.
View Article and Find Full Text PDFJ Am Chem Soc
January 2024
Department of Chemistry, Columbia University, New York, New York 10027, United States.
State-of-the-art methods in photoproximity labeling center on the targeted generation and capture of short-lived reactive intermediates to provide a snapshot of local protein environments. Diazirines are the current gold standard for high-resolution proximity labeling, generating short-lived aryl(trifluoromethyl) carbenes. Here, we present a method to access aryl(trifluoromethyl) carbenes from a stable diazo source tissue-penetrable, deep red to near-infrared light (600-800 nm).
View Article and Find Full Text PDFHeliyon
November 2023
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H1, Canada.
In the past decade, there has been increasing interest in use of small molecules for immunomodulation. The affinity-based pull-down purification is an essential tool for target identification of small molecules and drug discovery. This study presents our recent efforts to investigate the cellular target(s) of Compound A, a small molecule with demonstrated immunomodulatory properties in human peripheral blood mononuclear cells (PBMCs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!